Abstract Book

S695

ESTRO 37

respectively. For all patients – the radiotherapy plan was prepared with tangential fields for the breast/chest wall part of the volume. Anterior-posterior field arrangement was used for the supraclavicular and axillary area. Results The DIBH was very well tolerated by the patients. The duration of the breath hold was from 22 to 30 seconds. The mean anterior-posterior chest wall excursion during FB was 3.1 mm. With the DIBH, the front chest wall position was between 10 mm and 18 mm anteriorly to its mid-FB position. In the post-lumpectomy cases the portion of the heart that received more than 50% of the prescribed dose, was decreased from 2.07% to 0% (39.7 % max dose). At the same time, relative lung volume irradiated to >50% of the prescribed target dose was reduced from 17.63% (for FB) to 13.2% (for DIBH). In one extreme case with SCL nodes irradiation, the volume of the heart, receiving more than 50% of the prescribed dose, was: 5.74% for FB and 0% for DIBH (36% max dose); the ipsilateral lung received: 21.2% with FB and 8% with DIBH. In another case, where the SCL nodes were irradiated, the median relative heart volume receiving >50% of the prescribed dose was ~0 % for the both scans, but the max point dose was 77.5 % for FB and 11.4 % for DIBH. In a third case, the median relative heart volume receiving >50% of the prescribed dose was 12.21% for FB and 1.26% for DIBH. The median ipsilateral relative lung volume receiving >50% was higher for DIBH – 14.17% and 10.91% for FB. Conclusion This is the first study in Bulgaria, which demonstrates the dosimetric benefits of breathing adapted radiotherapy (BART). Our results showed that irradiated cardiac volumes can be consistently reduced for left-sided breast cancers by using DIBH. EP-1258 Impact of Patient-reported vs. Physician- reported outcome measures in breast cancer patients R. Carmona-Vigo 1 , L.A. Henríquez Hernández 1 , P.C. Lara Jiménez 1 1 Las Palmas de Gran Canaria, Radiation Oncology, Las Palmas de Gran Canaria, Spain Purpose or Objective Physician-reported outcomes for toxicity are used for defining the treatment schedule. Patient-reported outcomes (PRO) should also be taken in account. The aim of our study is to evaluate the relationship between Patient-reported vs. Physician-reported outcomes in patients with locally advanced breast cancer treated with hyperfractionated high dose radiotherapy. Material and Methods From 1991 to 2010, 184 patients affected by locally advanced breast cancer were included in a fase II protocol of hyperfractionated high dose radiotherapy with radical intent. In September 2011, a total of 56 patients were alive and in active follow-up. Three of them refused to participate, 2 had advanced age and another patient had Alzheimer disease. Fifty patients were evaluated for PRO by questionnaires QLQ-C30 and QLQ-BR23. Physician-reported outcomes were assessed by RTOG scale. Results Older patients and those with lymph node involvement showed worse HRQOL (p=0.008; p=0.013, respectively). The scale of sexual functioning, sexual enjoyment item, the item of concern for the future and scale of local breast symptoms are the worst rated, therefore the greatest impact on patients. No relationship between subcutaneous late toxicity recorded by the physician according to the RTOG scale and Quality of life perceived in any of the two questionnaires was found. A statistically significant inverse relationship between cutaneous late

toxicity and HRQOL was observed, so that patients with late cutaneous toxicity G3 has better HRQOL (FS: p=0.030; SS: p=0.010). Conclusion No relationship was observed between Patient-reported vs. Physician-reported outcomes. Physician scored toxicity should not be the only characteristic for defining treatments schedules. EP-1259 Breast Q questionnaires in Accelerated Partial Breast Irradiation: chasing the best quality of life M. Arangüena Peñacoba 1 , J.T. Anchuelo Latorre 1 , M.P. Galdós Barroso 1 , J. Andreescu Yagüe 1 , N. Sierrasesumaga Martín 1 , V. Cañón García 1 , F. Pozo Piñón 2 , P.J. Prada Gómez 1 1 Hospital Universitario Marqués de Valdecilla, Radiation Oncology, Santander, Spain 2 Hospital Universitario Marqués de Valdecilla, Radiology, Santander, Spain Purpose or Objective The objective of this study is to determine whether the type of Radiotherapy technique after Breast Conserving Therapy has an impact on patient-reported satisfaction and quality of life, as well as provide reliable and valid evidence regarding patient outcomes, as these variables are significantly growing importance when evaluating the The BREAST-Q is a patient-reported outcome (PRO) instrument designed to evaluate outcomes among women undergoing different types of breast surgery, especially we used the questionnaires for Postoperative module and the conversing tables for Breast Conserving Therapy, which transforms the punctuation of each variable to over 100. We compared two different Radiotherapy techniques, Accelerated Partial Breast Irradiation (APBI) with Brachytherapy in one 18 Gy fraction, and External Beam Radiotherapy (EBRT), hypo fractionated, in 15 fractions plus a boost of 3 fractions both in patients treated between 2015 and 2016. 25/25 questionnaires sent were filled of APBI and 18/25 of EBRT. Results We found that, in our study, patients treated with APBI had higher levels of satisfaction with the treated breast, better psychosocial, sexual and physical wellbeing and lower ratio of adverse effects of radiation than those who received EBRT, remaining the satisfaction with the team similar with both methods. Results in table 1. success of a treatment. Material and Methods

Conclusion APBI technique is an excellent therapy option. In addition, BREAST-Q questionnaires are a very useful tool to evaluate and provide subjective information of a treatment. EP-1260 Effectiveness, QoL and Toxicity of Intraoperative Radiotherapy in Early Breast Cancer Patients B. Urbanski 1 , A. Roszak 1 , P. Milecki 2 , A. Karczewska- Dzionk 3 1 Greater Poland Cancer Centre, Radiotherapy and Gyneacological Oncology Department, Poznan, Poland 2 Greater Poland Cancer Centre, Radiotherapy I Department, Poznan, Poland